Jump to Main Contents
ncc en

Annual Report 2020

Department of Diagnostic Pathology

Yasushi Yatabe, Shigeki Sekine, Nobuyoshi Hiraoka, Noriko Motoi, Akiko Maeshima, Taisuke Mori, Hirokazu Taniguchi, Masayuki Yoshida, Akihiko Yoshida, Hiroshi Yoshida, Kaishi Satomi, Taiki Hashimoto, Tomoaki Naka, Yuuki Nishimura, Junpei Yonemaru, Takeshi Ushikusa, Naoki Kojima, Nobuyasu Ikai, Natsumi Terada, Nami Yamamoto, Yuuka Takahashi, Sachiko Miura, Chizu Kina, Toshiko Sakaguchi, Shoichi Harada, Yuka Izumi, Aoi Miyata, Gulanbar Amori, Sachiyo Hasegawa, Yuko Kashiwazaki, Nozomi Handa, Takaaki Shiina, Kimii Shiba, Yukihiro Takeuchi

Introduction

 The Department of Diagnostic Pathology is responsible for histological and cytological diagnoses and autopsies in the National Cancer Center Hospital. In 2019, the department consisted of 12 staff pathologists, 7 residents, and 14 pathology technologists, including 12 cytotechnologists. We accepted a total of 25,502 histological specimens, including 20,806 biopsy and 4,696 surgically resected specimens and 12,731 cytological specimens (Table 1). These included 1,969 intraoperative frozen sections and 342 intraoperative cytological diagnoses. We also provided a total of 192 pathological diagnoses for the outpatient clinic via the pathology consultation system.

The Team and What We Do

 Accurate and precise histological and cytological diagnoses play a key role in cancer treatment provided in the hospital. The basis for diagnosis is gross observation and conventional hematoxylin-eosin staining of specimens, however, we also actively perform immunohistochemistry and special stain retrieval. In recent years, the detection of genetic abnormalities and expression of particular molecules has become more important in clinical practice, because several of the alterations have been used to select patients for molecular targeted therapy, treatment using immune checkpoint inhibitors, and prediction of clinical outcomes. Although the number of pathological autopsies has remained stable in recent years, the evaluation of the cause of death, the biological basis of the diseases, and therapeutic effects from the autopsy specimens is indispensable to contribute to and improve the quality of medical care in our hospital. This year, 21,424 biopsy and surgical specimens, 10,838 cytological diagnoses, and 14 autopsies were obtained (Table 1). We consider the connection to the clinical departments to be very important; thus, joint conferences are held regularly in addition to regular intradepartmental conferences and autopsy reviews.

 We also encourage research work, which are the studies for improving pathology diagnostics, clarifying biological features of diseases, and providing helpful findings for selecting therapeutic options.

Table 1. Number of specimens diagnosed in 2020
Table 1. Number of specimens diagnosed in 2020

Table 1. Number of specimens diagnosed in 2020
Table 1. Number of specimens diagnosed in 2020

Research activities

 Our department covers a wide range of research in pathology from basic to clinical aspects, which are conducted by the individual organ-based units, led by the section heads, including Drs. N. Hiraoka (hepatobiliary and pancreas malignancies), A. Maeshima (hematology), T. Mori (head and neck malignancies), K. Satomi (brain tumors), S. Sekine (gastrointestinal tracts), Y. Yatabe (thoracic malignancies), A. Yoshida (Bone and soft tissue malignancies), H. Yoshida (gynecologic), and M. Yoshida (breast malignancies).

Education

 We have actively accepted pathology residents and clinical fellows for pathology training and have sent many pathologists to work across the country. With the introduction of the specialist system, we have been operating a training program for board certification as a core-institution. At present, one senior resident, six residents and three trainees for the board certification program are enrolled in the department.

Future Prospects

 Our goal is to accomplish comprehensive pathological diagnoses, which are closely related to clinical practice, with the highest priority on medical safety. We will also train pathologists, who are in short supply in Japan, and provide training in pathology for tumor diagnoses. It is also important for us to develop research activities in cooperation with clinical departments and laboratories and to apply biological abnormalities in tumors to diagnoses.

List of papers published in 2020

Journal

1. Kobayashi K, Yoshimoto S, Ando M, Matsumoto F, Murakami N, Omura G, Honma Y, Matsumoto Y, Ikeda A, Sakai A, Eguchi K, Ito A, Ryo E, Yatabe Y, Mori T. Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence. Oral Oncol, 113:105091, 2021

2. Yoshida H, Nishikawa T, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Hasegawa K, Yonemori K. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Arch, 478:1161-1171, 2021

3. Shirasawa M, Yoshida T, Horinouchi H, Kitano S, Arakawa S, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Kanda S, Watanabe R, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment. Br J Cancer, 124:925-932, 2021

4. Shibayama T, Makise N, Motoi T, Mori T, Hiraoka N, Yonemori K, Watanabe SI, Esaki M, Morizane C, Okuma T, Kawai A, Ushiku T, Yatabe Y, Yoshida A. Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases: A Proposal of Risk Stratification and Identification of a Synaptophysin-positive Aggressive Subset. Am J Surg Pathol, 45:616-626, 2021

5. Nishida T, Matsumoto Y, Sasada S, Tanaka M, Nakai T, Fukai R, Ohe Y, Watanabe SI, Motoi N. Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessment. Jpn J Clin Oncol, 51:271-278, 2021

6. Takeyasu Y, Yoshida T, Shibaki R, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Yamamoto N, Motoi N, Ohe Y. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≧50%) NSCLC. Clin Lung Cancer, 22:127-133.e3, 2021

7. Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y. HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs. Thorac Cancer, 12:631-642, 2021

8. Arakawa S, Yoshida T, Shirasawa M, Takayanagi D, Yagishita S, Motoi N, Ohe Y. RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient. Lung Cancer, 151:101-103, 2021

9. Takahashi T, Umeguchi H, Tateishi A, Yoshida T, Motoi N, Ohe Y. Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib. Lung Cancer, 151:1-4, 2021

10. Cho H, Yamada M, Sekine S, Tanabe N, Ushiama M, Hirata M, Ogawa G, Gotoh M, Yoshida T, Yoshikawa T, Saito Y, Kuchiba A, Oda I, Sugano K. Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis. Gastric Cancer, 24:283-291, 2021

11. Tsutsui K, Namikawa K, Mori T, Kato K, Jinnai S, Nakama K, Ogata D, Takahashi A, Yamazaki N. Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. J Dermatol, 48:e114-e115, 2021

12. Iwasaki T, Nara S, Nishimura Y, Ueda H, Kishi Y, Esaki M, Shimada K, Hiraoka N. Postoperative acute multiple organ failure after hepatectomy in a Nigerian male with sickle cell trait: a case report. Surg Case Rep, 7:19, 2021

13. Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiraoka N, Ito Y, Katayama H, Ueno M, Ikeda M, Sugimori K, Okano N, Shimizu K, Yanagimoto H, Okusaka T, Ozaka M, Todaka A, Nakamori S, Tobimatsu K, Sata N, Kawashima Y, Hosokawa A, Yamaguchi T, Miyakawa H, Hara H, Mizuno N, Ishii H. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol, 51:235-243, 2021

14. Kato MK, Yoshida H, Uehara T, Uno M, Ishikawa M, Miyasaka N, Kato T. Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center. Taiwan J Obstet Gynecol, 60:238-244, 2021

15. Yoshida H, Tanaka H, Tsukada T, Abeto N, Kobayashi-Kato M, Tanase Y, Uno M, Ishikawa M, Kato T. Gross mucinous multinodular appearance aids in the identification of ovarian metastases in low-grade appendiceal mucinous neoplasms during intraoperative consultation. Ann Diagn Pathol, 50:151641, 2021

16. Yoshida H, Tanaka H, Tsukada T, Abeto N, Kobayashi-Kato M, Tanase Y, Uno M, Ishikawa M, Kato T. Diagnostic Discordance in Intraoperative Frozen Section Diagnosis of Ovarian Tumors: A Literature Review and Analysis of 871 Cases Treated at a Japanese Cancer Center. Int J Surg Pathol, 29:30-38, 2021

17. Muto Y, Ryo E, Namikawa K, Takahashi A, Ogata D, Fujimura T, Yatabe Y, Aiba S, Yamazaki N, Mori T. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma. Pathol Int, 71:337-347, 2021

18. Kashima J, Yoshida M, Jimbo K, Izutsu K, Ushiku T, Yonemori K, Yoshida A. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology. Am J Surg Pathol, 45:347-355, 2021

19. Nozaki K, Maruyama D, Maeshima AM, Tajima K, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Izutsu K, Tobinai K. The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma. Eur J Haematol, 106:213-220, 2021

20. Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, Takahashi K, Okamoto A, Hirabayashi S, Hasegawa D, Manabe A, Ono K, Matsuoka M, Arai Y, Togashi Y, Shibata T, Nishikawa H, Aoki K, Yamamoto N, Kohno T, Ogawa C. Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. N Engl J Med, 384:42-50, 2021

21. Takamizawa S, Honma Y, Murakami N, Mori T, Oka H, Yamamoto S, Kashihara T, Ito K, Kubo Y, Ikeda A, Matsumoto F, Omura G, Kobayashi K, Itami J, Kato K, Yoshimoto S. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma. Invest New Drugs, 39:564-570, 2021

22. Murakami N, Mori T, Machida R, Kodaira T, Ito Y, Shikama N, Konishi K, Matsumoto Y, Murakami Y, Nakamura N, Yamashita H, Yorozu A, Yoshimura M, Inoue K, Nozaki M, Ishikura S, Itami J, Nishimura Y, Kagami Y. Prognostic Value of Epithelial Cell Adhesion Molecules in T1-2N0M0 Glottic Cancer. Laryngoscope, 131:1522-1527, 2021

23. Endo Y, Fujimoto M, Ito N, Takahashi Y, Kitago M, Gotoh M, Hiraoka N, Yoshida T, Kitagawa Y, Kanai Y, Arai E. Clinicopathological impacts of DNA methylation alterations on pancreatic ductal adenocarcinoma: prediction of early recurrence based on genome-wide DNA methylation profiling. J Cancer Res Clin Oncol, 147:1341-1354, 2021

24. Honda K, Hishiki T, Yamamoto S, Yamamoto T, Miura N, Kubo A, Itoh M, Chen WY, Takano M, Yoshikawa T, Kasamatsu T, Sonoda S, Yoshizawa H, Nakamura S, Itai Y, Shiota M, Koike D, Naya M, Hayakawa N, Naito Y, Matsuura T, Iwaisako K, Masui T, Uemoto S, Nagashima K, Hashimoto Y, Sakuma T, Matsubara O, Huang W, Ida T, Akaike T, Masugi Y, Sakamoto M, Kato T, Ino Y, Yoshida H, Tsuda H, Hiraoka N, Kabe Y, Suematsu M. On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biol, 41:101926, 2021

25. Karigane D, Kasahara H, Shiroshita K, Fujita S, Kobayashi H, Tamaki S, Yamazaki R, Yahagi K, Yatabe Y, Kondoh N, Arai T, Katagiri H, Shimizu N, Sakurai M, Kikuchi T, Kato J, Shimizu T, Hayakawa T, Yaguchi T, Matsushita M, Nakajima H, Kawakami Y, Murata M, Mori T, Sasaki T, Okamoto S, Takubo K. Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph+ B cells but not bone marrow stem/progenitors. Leuk Lymphoma, 62:679-687, 2021

26. Kikkawa N, Ito K, Yoshida H, Kato MK, Kubo Y, Onishi Y, Sugawara H, Kato T, Kusumoto M. Magnetic resonance imaging findings in 11 cases of dedifferentiated endometrial carcinoma of the uterus. Jpn J Radiol, 39:477-486, 2021

27. Meng X, Matsumoto F, Mori T, Miura N, Ino Y, Onidani K, Kobayashi K, Matsuzaki Y, Yoshimoto S, Ikeda K, Honda K. BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Anticancer Res, 41:1089-1099, 2021

28. Mino-Kenudson M, Le Stang N, Daigneault JB, Nicholson AG, Cooper WA, Roden AC, Moreira AL, Thunnissen E, Papotti M, Pelosi G, Motoi N, Poleri C, Brambilla E, Redman M, Jain D, Dacic S, Yatabe Y, Tsao MS, Lopez-Rios F, Botling J, Chen G, Chou TY, Hirsch FR, Beasley MB, Borczuk A, Bubendorf L, Chung JH, Hwang D, Lin D, Longshore J, Noguchi M, Rekhtman N, Sholl L, Travis W, Yoshida A, Wynes MW, Wistuba II, Kerr KM, Lantuejoul S. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. J Thorac Oncol, 16:686-696, 2021

29. Naruse M, Ochiai M, Sekine S, Taniguchi H, Yoshida T, Ichikawa H, Sakamoto H, Kubo T, Matsumoto K, Ochiai A, Imai T. Re-expression of REG family and DUOXs genes in CRC organoids by co-culturing with CAFs. Sci Rep, 11:2077, 2021

30. Onishi Y, Kusumoto M, Motoi N, Hiraoka N, Sugawara S, Itou C, Sone M. Natural History of Epithelioid Hemangioendothelioma of the Liver: CT Findings of 15 Cases. Acad Radiol, 28:778-782, 2021

31. Ota M, Nakatani Y, Nakajima T, Hiroshima K, Motoi N, Yoshino I, Ikeda JI. Pulmonary microinvasive small cell carcinoma with an extensive in-situ component identified after photodynamic therapy for 'squamous cell carcinoma in situ': a case report. Histopathology, 78:912-916, 2021

32. Ota Y, Noguchi T, Ariji E, Fushimi C, Fuwa N, Harada H, Hayashi T, Hayashi R, Honma Y, Miura M, Mori T, Nagatsuka H, Okura M, Ueda M, Uzawa N, Yagihara K, Yagishita H, Yamashiro M, Yanamoto S, Kirita T. General rules for clinical and pathological studies on oral cancer (2nd edition): a synopsis. Int J Clin Oncol, 26:623-635, 2021

33. Sakao Y, Kuroda H, Saito Y, Yamauchi Y, Yokote F, Kawamura M, Yatabe Y. Radiological imaging and pathological findings of small lung adenocarcinoma: a narrative review. J Thorac Dis, 13:366-371, 2021

34. Sugano T, Masuda M, Takeshita F, Motoi N, Hirozane T, Goto N, Kashimoto S, Uno Y, Moriyama H, Sawa M, Nagakawa Y, Tsuchida A, Seike M, Gemma A, Yamada T. Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. Br J Cancer, 124:228-236, 2021

35. Suzuki T, Fukuhara S, Nomoto J, Yamashita S, Maeshima AM, Ito Y, Hatta S, Yuda S, Makita S, Munakata W, Suzuki T, Maruyama D, Taniguchi H, Ushijima T, Izutsu K, Tobinai K, Kobayashi Y. Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors. Haematologica, 106:593-596, 2021

36. Takeyasu Y, Yoshida T, Motoi N, Teishikata T, Tanaka M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Kakishima H, Tsuchida T, Yamamoto N, Ohe Y, Yatabe Y. Feasibility of next-generation sequencing (Oncomine DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients. Jpn J Clin Oncol, 2021

37. Ueda S, Yamashita S, Watanabe SI, Wakabayashi M, Motoi N, Noguchi M, Sekine S, Sato Y, Ushijima T. Influence of degree of DNA degradation in formalin-fixed and paraffin-embedded tissue samples on accuracy of genome-wide DNA methylation analysis. Epigenomics, 13:565-576, 2021

38. Uehara T, Yoshida H, Kato T. Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy. Gynecol Oncol Rep, 35:100692, 2021

39. Yagishita S, Kato K, Takahashi M, Imai T, Yatabe Y, Kuwata T, Suzuki M, Ochiai A, Ohtsu A, Shimada K, Nishida T, Hamada A, Mano H. Characterization of the large-scale Japanese patient-derived xenograft (J-PDX) library. Cancer Sci, 112:2454-2466, 2021

40. Yasukawa Y, Hattori N, Iida N, Takeshima H, Maeda M, Kiyono T, Sekine S, Seto Y, Ushijima T. SAA1 is upregulated in gastric cancer-associated fibroblasts possibly by its enhancer activation. Carcinogenesis, 42:180-189, 2021

41. Yatabe Y, Yoshiki Y, Matsumura K, Togo K, Kikkawa H, Iadeluca L, Li B, Nishio K. Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan. JTO Clinical and Research Reports, 2:100136, 2021

42. Yonemaru J, Hashimoto T, Takayanagi D, Naka T, Yatabe Y, Kanemitsu Y, Shiraishi K, Sekine S. NTRK fusion-positive colorectal cancer in Japanese population. Pathol Int, 71:355-359, 2021

43. Yorozu T, Nagahama K, Morii T, Maeda D, Yoshida A, Mori T, Hayashi A, Shibahara J. Myoepithelioma-like Hyalinizing Epithelioid Tumor of the Foot Harboring an OGT-FOXO1 Fusion. Am J Surg Pathol, 45:287-290, 2021

44. Yoshida A, Hashimoto T, Ryo E, Yoshida KI, Motoi T, Yatabe Y, Mori T. Confirmation of NKX3-1 Expression in EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma Using Monoclonal Antibody Immunohistochemistry, RT-PCR, and RNA In Situ Hybridization. Am J Surg Pathol, 45:578-582, 2021

45. Yoshida H, Naka T, Kobayashi-Kato M, Kikkawa N, Tanase Y, Uno M, Ishikawa M, Kato T. Gastric-type cervical adenocarcinoma with squamous differentiation: buried in adenosquamous carcinomas? Virchows Arch, 2021

46. Miki S, Satomi K, Ohno M, Matsushita Y, Kitahara M, Miyakita Y, Takahashi M, Matsuda M, Ishikawa E, Matsumura A, Yoshida A, Narita Y, Ichimura K. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR. Brain Tumor Pathol, 37:154-158, 2020

47. Matsuzuka T, Uemura H, Yoshimoto S, Miura K, Shiotani A, Sugasawa M, Homma A, Yokoyama J, Tsukahara K, Yoshizaki T, Yatabe Y, Kobari T, Kosuda S, Murono S, Hasegawa Y. Attempting to define sentinel node micrometastasis in oral squamous cell carcinoma. Fukushima J Med Sci, 66:143-147, 2020

48. Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Shimomura A, Noguchi E, Kato T, Shimoi T, Uno M, Ishikawa M, Fujiwara Y, Ohe Y, Tamura K. HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix. Oncol Lett, 20:38, 2020

49. Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kanai Y, Kohno T. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Breast Cancer Res Treat, 182:491-502, 2020

50. Shirasawa M, Yoshida T, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. Eur J Cancer, 140:28-36, 2020

51. Watanabe S, Shimomura A, Kubo T, Sekimizu M, Seo T, Watanabe SI, Kawai A, Yamamoto N, Tamura K, Kohno T, Ichikawa H, Yoshida A. BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma. Mod Pathol, 33:1660-1668, 2020

52. Yoshida Y, Yotsukura M, Nakagawa K, Watanabe H, Motoi N, Watanabe SI. Surgical Results in Pathological N1 Nonsmall Cell Lung Cancer. Thorac Cardiovasc Surg, 2020

53. Miyanaga A, Masuda M, Motoi N, Tsuta K, Nakamura Y, Nishijima N, Watanabe SI, Asamura H, Tsuchida A, Seike M, Gemma A, Yamada T. Whole-exome and RNA sequencing of pulmonary carcinoid reveals chromosomal rearrangements associated with recurrence. Lung Cancer, 145:85-94, 2020

54. Yotsukura M, Asamura H, Suzuki S, Asakura K, Yoshida Y, Nakagawa K, Sakurai H, Watanabe SI, Motoi N. Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma. Lung Cancer, 145:158-166, 2020

55. Makise N, Mori T, Kobayashi H, Nakagawa K, Ryo E, Nakajima J, Kohsaka S, Mano H, Aburatani H, Yoshida A, Ushiku T. Mesenchymal tumours with RREB1-MRTFB fusion involving the mediastinum: extra-glossal ectomesenchymal chondromyxoid tumours? Histopathology, 76:1023-1031, 2020

56. Onishi Y, Ito K, Motoi N, Morita T, Watanabe SI, Kusumoto M. Ciliated muconodular papillary tumor of the lung: 18F-FDG PET/CT findings of 15 cases. Ann Nucl Med, 34:448-452, 2020

57. Yotsukura M, Asamura H, Suzuki S, Asakura K, Yoshida Y, Nakagawa K, Sakurai H, Watanabe SI, Motoi N. Histological and prognostic data on surgically resected early-stage lung adenocarcinoma. Data Brief, 31:105785, 2020

58. Onishi Y, Kusumoto M, Motoi N, Watanabe H, Watanabe SI. Ciliated Muconodular Papillary Tumor of the Lung: Thin-Section CT Findings of 16 Cases. AJR Am J Roentgenol, 214:761-765, 2020

59. Inaba-Higashiyama R, Yoshida T, Jo H, Shirasawa M, Motoi N, Ohe Y. Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≧3) and high PD-L1 expression (TPS ≧50%): A case series. Thorac Cancer, 11:3618-3621, 2020

60. Onishi Y, Kusumoto M, Goto Y, Kaku S, Motoi N. Epithelioid hemangioendothelioma of the lung: CT findings and clinical course of 35 cases. Jpn J Clin Oncol, 50:1195-1200, 2020

61. Sato J, Kitano S, Motoi N, Ino Y, Yamamoto N, Watanabe S, Ohe Y, Hiraoka N. CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma. Cancer Sci, 111:1921-1932, 2020

62. Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol, 15:709-740, 2020

63. Kamiya A, Yamagata Y, Yoshida H, Ishizu K, Wada T, Hayashi T, Otsuki S, Yoshikawa T, Katai H. Laparoscopic resection of a primary diaphragmatic schwannoma: a case report and literature review. BMC Surg, 20:289, 2020

64. Kanamori K, Yamagata Y, Honma Y, Date K, Wada T, Hayashi T, Otsuki S, Sekine S, Yoshikawa T, Katai H, Nishida T. Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review. World J Surg Oncol, 18:183, 2020

65. Kato MK, Shida D, Yoneoka Y, Yoshida H, Miyasaka N, Kanemitsu Y, Kato T. Novel classification of ovarian metastases originating from colorectal cancer by radiological imaging and macroscopic appearance. Int J Clin Oncol, 25:1663-1671, 2020

66. Tamura N, Honma Y, Sekine S, Tsukamoto S, Hirano H, Okita N, Shoji H, Iwasa S, Takashima A, Kato K, Boku N. Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy. Oxf Med Case Reports, 2020:omaa097, 2020

67. Sekine S, Yamashita S, Yamada M, Hashimoto T, Ogawa R, Yoshida H, Taniguchi H, Kojima M, Ushijima T, Saito Y. Clinicopathological and molecular correlations in traditional serrated adenoma. J Gastroenterol, 55:418-427, 2020

68. Kasuga K, Sakamoto T, Takamaru H, Sekiguchi M, Yamada M, Yamazaki N, Hashimoto T, Uraoka T, Saito Y. Endoscopic reduction of colocolonic intussusception due to metastatic malignant melanoma: A case report. World J Clin Cases, 8:5816-5820, 2020

69. Okamura T, Hashimoto T, Naka T, Yoshida T, Tanabe N, Ogawa R, Yamada M, Saito Y, Yatabe Y, Sekine S. Clinicopathologic and Molecular Characteristics of Familial Adenomatous Polyposis-associated Traditional Serrated Adenoma. Am J Surg Pathol, 44:1282-1289, 2020

70. Nonaka S, Hashimoto T, Oda I, Sekine S. Sporadic pyloric gland adenoma associated with a large fundic gland polyp: genetic evidence for stepwise progression. Gastric Cancer, 23:1102-1106, 2020

71. Hiraoka N, Nitta H, Ohba A, Yoshida H, Morizane C, Okusaka T, Nara S, Esaki M, Kishi Y, Shimada K. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Hum Pathol, 105:9-19, 2020

72. Watanabe H, Yamazaki Y, Fujishima F, Izumi K, Imamura M, Hijioka S, Toriyama K, Yatabe Y, Kudo A, Motoi F, Unno M, Sasano H. O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms. BMC Cancer, 20:1195, 2020

73. Fujimoto M, Arai E, Tsumura K, Yotani T, Yamada Y, Takahashi Y, Maeshima AM, Fujimoto H, Yoshida T, Kanai Y. Establishment of diagnostic criteria for upper urinary tract urothelial carcinoma based on genome-wide DNA methylation analysis. Epigenetics, 15:1289-1301, 2020

74. Kojima N, Kuno I, Ushigusa T, Kato T, Yoshida H. Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy. Virchows Arch, 477:429-436, 2020

75. Uehara T, Yoshida H, Fukuhara M, Yoshida M, Motoi N, Sugawara S, Sone M, Arai Y, Tamura K, Uno M, Ishikawa M, Kato T. Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites. Gynecol Oncol, 157:398-404, 2020

76. Mizuta H, Takahashi A, Mori T, Namikawa K, Nakano E, Muto Y, Jinnai S, Nakama K, Tsutsui K, Yamazaki N. Efficacy of oral retinoids for keratoacanthoma centrifugum marginatum. Dermatol Ther, 33:e13291, 2020

77. Tsutsui K, Namikawa K, Mori T, Jinnai S, Nakama K, Ogata D, Takahashi A, Yamazaki N. Case of multiple ectopic extramammary Paget's disease of the trunk. J Dermatol, 47:e329-e331, 2020

78. Maeshima AM, Taniguchi H, Fujino T, Saito Y, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. Ann Hematol, 99:2141-2148, 2020

79. Maeshima AM, Taniguchi H, Ida H, Hosoba R, Fujino T, Saito Y, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K. Non-diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases. Hum Pathol, 102:33-43, 2020

80. Saito Y, Makita S, Chinen S, Kito M, Fujino T, Ida H, Hosoba R, Tanaka T, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Miyagi-Maeshima A, Matsushita H, Izutsu K. Acute megakaryoblastic leukaemia with t(1;22)(p13?3;q13?1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour. Br J Haematol, 190:e329-e332, 2020

81. Makita S, Maruyama D, Maeshima AM, Taniguchi H, Yuda S, Toyoda K, Yamauchi N, Fukuhara S, Munakata W, Kobayashi Y, Kurihara H, Izutsu K, Tobinai K. A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma. Asia Pac J Clin Oncol, 16:108-114, 2020

82. Shichijo T, Maruyama D, Yamauchi N, Maeshima AM, Sugano M, Yuda S, Tajima K, Kurihara H, Shimada K, Suzuki T, Toyoda K, Makita S, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Taniguchi H, Minami Y, Izutsu K, Tobinai K. Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma. Cancer Med, 9:8864-8874, 2020

83. Kuno M, Ito A, Maeshima AM, Taniguchi H, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, Fukuda T. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Int J Hematol, 112:193-199, 2020

84. Tamura N, Fujiwara Y, Hashimoto T, Shiraishi H, Kitano S, Shimizu T, Kuwano K, Yamamoto N, Motoi N. Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma. Lung Cancer, 145:152-157, 2020

85. Hosoba R, Makita S, Shiotsuka M, Kobayashi O, Nakano K, Muroya M, Okada N, Suzuki M, Ida H, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Maeshima AM, Matsushita H, Yamamoto N, Ohe Y, Iwata S, Izutsu K. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. J Clin Exp Hematop, 60:174-178, 2020

86. Arakawa S, Yoshida T, Nakayama Y, Motoi N, Ohe Y. Small Cell Cancer Transformation of Lung Adenocarcinoma During Durvalumab Treatment After Chemoradiotherapy. J Thorac Oncol, 15:e145-e146, 2020

87. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun, 11:4748, 2020

88. Chatani S, Hasegawa T, Kato S, Murata S, Sato Y, Yamaura H, Yamamoto K, Yatabe Y, Inaba Y. Image-guided core needle biopsy in the diagnosis of malignant lymphoma: comparison with surgical excision biopsy. Eur J Radiol, 127:108990, 2020

89. Doi N, Ino Y, Angata K, Shimada K, Narimatsu H, Hiraoka N. Clinicopathological significance of core 3 O-glycan synthetic enzyme, β1,3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma. PLoS One, 15:e0242851, 2020

90. Edwards JG, Chansky K, Van Schil P, Nicholson AG, Boubia S, Brambilla E, Donington J, Galateau-Sallé F, Hoffmann H, Infante M, Marino M, Marom EM, Nakajima J, Ostrowski M, Travis WD, Tsao MS, Yatabe Y, Giroux DJ, Shemanski L, Crowley J, Krasnik M, Asamura H, Rami-Porta R. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol, 15:344-359, 2020

91. Fujiyoshi T, Tajika M, Tanaka T, Ishihara M, Mizuno N, Hara K, Hijioka S, Imaoka H, Yatabe Y, Hirooka Y, Goto H, Yamao K, Niwa Y. Corrigendum to: Comparative evaluation of new and conventional classifications of magnifying endoscopy with narrow band imaging for invasion depth of superficial esophageal squamous cell carcinoma. Dis Esophagus, 33:2020

92. Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, Miyata H, Nagahashi M, Niikura N, Ogo E, Tamura K, Tanakura K, Yamamoto Y, Yoshida M, Imoto S, Jinno H. Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer, 27:803-809, 2020

93. Hiraoka N, Ino Y, Hori S, Yamazaki-Itoh R, Naito C, Shimasaki M, Esaki M, Nara S, Kishi Y, Shimada K, Nakamura N, Torigoe T, Heike Y. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Cancer Sci, 111:3057-3070, 2020

94. Hiroshima K, Yoshizawa A, Takenaka A, Haba R, Kawahara K, Minami Y, Kakinuma H, Shibuki Y, Miyake S, Kajio K, Miyamoto K, Nagatomo M, Nishimura S, Mano M, Matsubayashi J, Motoi N, Nagao T, Nakatsuka SI, Yoshida T, Satoh Y. Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and Japanese Society of Clinical Cytology: An Interobserver Reproducibility Study and Risk of Malignancy Evaluation on Cytology Specimens. Acta Cytol, 64:452-462, 2020

95. Hori Y, Maruyama D, Maeshima AM, Ida H, Kurihara H, Izutsu K. Neurolymphomatosis detected by 18F-fluorodeoxyglucose-positron emission tomography. eJHaem, 1:19-20, 2020

96. Ichikawa A, Fujita Y, Hosaka Y, Kadota T, Ito A, Yagishita S, Watanabe N, Fujimoto S, Kawamoto H, Saito N, Yoshida M, Hashimoto M, Minagawa S, Hara H, Motoi N, Yamamoto Y, Ochiya T, Araya J, Kuwano K. Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer. Cancer Sci, 111:4154-4165, 2020

97. Ida H, Maruyama D, Maeshima AM, Kamiya T, Morio T, Izutsu K. Duodenal nodular lymphoid hyperplasia in a patient with IgA deficiency. Clin Case Rep, 8:3594-3595, 2020

98. Ito M, Kanda S, Yoshida T, Okuma Y, Jo H, Fukuhara S, Maeshima AM, Ohe Y. Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient. Lung Cancer, 146:362-365, 2020

99. Jimbo K, Kinoshita T, Ogura T, Watase C, Murata T, Shiino S, Takayama S, Yoshida M. Prediction score model for non-sentinel and four or more nodal metastases using a combined method of one-step nucleic acid amplification and histology in sentinel node-positive breast cancer patients. Eur J Surg Oncol, 46:516-521, 2020

100. Kawasaki K, Toshimitsu K, Matano M, Fujita M, Fujii M, Togasaki K, Ebisudani T, Shimokawa M, Takano A, Takahashi S, Ohta Y, Nanki K, Igarashi R, Ishimaru K, Ishida H, Sukawa Y, Sugimoto S, Saito Y, Maejima K, Sasagawa S, Lee H, Kim HG, Ha K, Hamamoto J, Fukunaga K, Maekawa A, Tanabe M, Ishihara S, Hamamoto Y, Yasuda H, Sekine S, Kudo A, Kitagawa Y, Kanai T, Nakagawa H, Sato T. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell, 183:1420-1435.e21, 2020

101. Kubo M, Kumamaru H, Isozumi U, Miyashita M, Nagahashi M, Kadoya T, Kojima Y, Aogi K, Hayashi N, Tamura K, Asaga S, Niikura N, Ogo E, Iijima K, Tanakura K, Yoshida M, Miyata H, Yamamoto Y, Imoto S, Jinno H. Annual report of the Japanese Breast Cancer Society registry for 2016. Breast Cancer, 27:511-518, 2020

102. Kuwata T, Wakabayashi M, Hatanaka Y, Morii E, Oda Y, Taguchi K, Noguchi M, Ishikawa Y, Nakajima T, Sekine S, Nomura S, Okamoto W, Fujii S, Yoshino T. Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN. Pathol Int, 70:932-942, 2020

103. Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba II, Mino-Kenudson M. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. J Thorac Oncol, 15:499-519, 2020

104. Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, Boutros PC. Sex differences in oncogenic mutational processes. Nat Commun, 11:4330, 2020

105. Maeshima AM, Maejima A, Shinoda Y, Matsui Y, Komiyama M, Fujimoto H. Prostatic specific antigen-positive adenocarcinoma arising from a stromal tumor of uncertain malignant potential in the M?llerian cyst of the male genital tract: A case report. Human Pathology: Case Reports, 21:200395, 2020

106. Matsuda K, Kashima J, Yatabe Y. The Isoform Matters in NUT Carcinoma: A Diagnostic Pitfall of p40 Immunohistochemistry. J Thorac Oncol, 15:e176-e178, 2020

107. Matsui T, Sakakura N, Koyama S, Nakanishi K, Sasaki E, Kato S, Hosoda W, Murakami Y, Kuroda H, Yatabe Y. Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma. Ann Thorac Surg, 2020

108. Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y, Cooper WA, Yoshida A, Bubendorf L, Papotti M, Pelosi G, Lopez-Rios F, Kunitoki K, Ferrari-Light D, Sholl LM, Beasley MB, Borczuk A, Botling J, Brambilla E, Chen G, Chou TY, Chung JH, Dacic S, Jain D, Hirsch FR, Hwang D, Lantuejoul S, Lin D, Longshore JW, Motoi N, Noguchi M, Poleri C, Rekhtman N, Tsao MS, Thunnissen E, Travis WD, Yatabe Y, Roden AC, Daigneault JB, Wistuba II, Kerr KM, Pass H, Nicholson AG, Mino-Kenudson M. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol, 15:1599-1610, 2020

109. Morita S, Suda T, Kishi Y, Iwasaki T, Hiraoka N, Nagayama I, Hoshi T, Abe S, Yagi K, Hasegawa G, Ikarashi T, Terai S. Synchronous Double Bile Duct Cancers with Distinct Genetic Features. Intern Med, 59:2129-2134, 2020

110. Motoi N, Yatabe Y. Lung cancer biomarker tests: the history and perspective in Japan. Transl Lung Cancer Res, 9:879-886, 2020

111. Nakajima K, Ino Y, Yamazaki-Itoh R, Naito C, Shimasaki M, Takahashi M, Esaki M, Nara S, Kishi Y, Shimada K, Hiraoka N. IAP inhibitor, Embelin increases VCAM-1 levels on the endothelium, producing lymphocytic infiltration and antitumor immunity. Oncoimmunology, 9:1838812, 2020

112. Nakano Y, Yamasaki K, Satomi K, Fukushima H, Okuhiro Y, Okada K, Osugi Y, Sakamoto H, Inoue T, Yoshida A, Ichimura K, Hara J. A case of pediatric gliomatosis cerebri harboring H3F3A K27 mutation. Pediatr Blood Cancer, 67:e28270, 2020

113. Namikawa K, Takahashi A, Mori T, Tsutsumida A, Suzuki S, Motoi N, Jinnai S, Kage Y, Mizuta H, Muto Y, Nakano E, Yamazaki N. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study. Melanoma Res, 30:76-84, 2020

114. Nishino T, Aruga Y, Ikeda C, Maeshima AM, Maruyama D, Matsushita H. Mixed-phenotype acute leukaemia consisting of five heterogeneous leukaemic populations without the expression of CD34. eJHaem, 1:406-407, 2020

115. No? M, Niknafs N, Fischer CG, Hackeng WM, Beleva Guthrie V, Hosoda W, Debeljak M, Papp E, Adleff V, White JR, Luchini C, Pea A, Scarpa A, Butturini G, Zamboni G, Castelli P, Hong SM, Yachida S, Hiraoka N, Gill AJ, Samra JS, Offerhaus GJA, Hoorens A, Verheij J, Jansen C, Adsay NV, Jiang W, Winter J, Albores-Saavedra J, Terris B, Thompson ED, Roberts NJ, Hruban RH, Karchin R, Scharpf RB, Brosens LAA, Velculescu VE, Wood LD. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat Commun, 11:4085, 2020

116. Numakura S, Saito K, Motoi N, Mori T, Saito Y, Yokote F, Kanamoto Y, Asami M, Sakai T, Yamauchi Y, Sakao Y, Uozaki H, Kawamura M. P63-negative pulmonary NUT carcinoma arising in the elderly: a case report. Diagn Pathol, 15:134, 2020

117. Ogiya R, Niikura N, Kumamaru H, Takeuchi Y, Okamura T, Kinoshita T, Aogi K, Anan K, Iijima K, Ishida T, Iwamoto T, Kawai M, Kojima Y, Sakatani T, Sagara Y, Hayashi N, Masuoka H, Yoshida M, Miyata H, Tsuda H, Imoto S, Jinno H. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. Breast Cancer Res Treat, 184:585-596, 2020

118. Ogura M, Kiyuna T, Yoshida H. Impact of blurs on machine-learning aided digital pathology image analysis. Artif Intell Cancer, 1:31-38, 2020

119. Sakakibara R, Kobayashi M, Takahashi N, Inamura K, Ninomiya H, Wakejima R, Kitazono S, Yanagitani N, Horiike A, Ichinose J, Matsuura Y, Nakao M, Mun M, Nishio M, Okumura S, Motoi N, Ito T, Miyazaki Y, Inase N, Ishikawa Y. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56. Am J Surg Pathol, 44:757-764, 2020

120. Sakamoto Y, Xu L, Seki M, Yokoyama TT, Kasahara M, Kashima Y, Ohashi A, Shimada Y, Motoi N, Tsuchihara K, Kobayashi SS, Kohno T, Shiraishi Y, Suzuki A, Suzuki Y. Long-read sequencing for non-small-cell lung cancer genomes. Genome Res, 30:1243-1257, 2020

121. Sasaki E, Masago K, Fujita S, Hanai N, Yatabe Y. Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck. J Pathol Clin Res, 6:154-159, 2020

122. Sasaki T, Gokita T, Ae K, Tanizawa T, Hayakawa K, Funauchi Y, Motoi N, Matsumoto S. Osteosarcoma arising from acetabulum extended to femoral head through round ligament: a case report. Oxf Med Case Reports, 2020:omaa076, 2020

123. Satomi K, Jimbo K, Shimizu C, Sekine C, Iwamoto E, Murata T, Shiino S, Takayama S, Maeshima A, Kinoshita T, Tamura K, Yoshida M. Unusual S-100 and SOX10 immunoreactivity in a case of basal-HER2 metaplastic carcinoma of the breast: A potential diagnostic pitfall. Human Pathology: Case Reports, 21:200394, 2020

124. Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, Shimomura A, Yonemori K, Fujiwara Y, Tamura K. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Rep Oncol Med, 2020:2518383, 2020

125. Seto K, Haneda M, Masago K, Fujita S, Kato S, Sasaki E, Hosoda W, Murakami Y, Kuroda H, Horio Y, Hida T, Okubo K, Yatabe Y. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF. Pathol Int, 70:253-261, 2020

126. Shiino S, Yoshida M, Tokura M, Watase C, Murata T, Jimbo K, Takayama S, Suto A, Satomi K, Miyagi Maeshima A, Kikuchi M, Uchiyama N, Kinoshita T. Locally advanced triple negative breast cancer arising from fibroadenoma with complete response to neoadjuvant chemotherapy: A case report. Int J Surg Case Rep, 68:234-238, 2020

127. Shiokawa D, Sakai H, Ohata H, Miyazaki T, Kanda Y, Sekine S, Narushima D, Hosokawa M, Kato M, Suzuki Y, Takeyama H, Kambara H, Nakagama H, Okamoto K. Slow-Cycling Cancer Stem Cells Regulate Progression and Chemoresistance in Colon Cancer. Cancer Res, 80:4451-4464, 2020

128. Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A, Brambilla E, Chen G, Chou TY, Chung JH, Cooper WA, Dacic S, Lantuejoul S, Jain D, Lin D, Minami Y, Moreira A, Nicholson AG, Noguchi M, Papotti M, Pelosi G, Poleri C, Rekhtman N, Tsao MS, Thunnissen E, Travis W, Yatabe Y, Yoshida A, Daigneault JB, Zehir A, Peters S, Wistuba II, Kerr KM, Longshore JW. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol, 15:1409-1424, 2020

129. Sugano T, Yoshida M, Masuda M, Ono M, Tamura K, Kinoshita T, Tsuda H, Honda K, Gemma A, Yamada T. Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma. Br J Cancer, 122:1811-1817, 2020

130. Takadera M, Satomi K, Szulzewsky F, Cimino PJ, Holland EC, Yamamoto T, Ichimura K, Ozawa T. Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes. Acta Neuropathol Commun, 8:203, 2020

131. Taniguchi H, Uehara K, Nakayama G, Nakayama H, Aiba T, Hattori N, Kataoka M, Nakano Y, Kawase Y, Okochi O, Matsuoka H, Utsunomiya S, Sakamoto E, Mori Y, Umeda S, Shikano T, Komori K, Tajika M, Kadowaki S, Muro K, Yatabe Y. Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. Transl Oncol, 13:100786, 2020

132. Tian Y, Arai E, Makiuchi S, Tsuda N, Kuramoto J, Ohara K, Takahashi Y, Ito N, Ojima H, Hiraoka N, Gotoh M, Yoshida T, Kanai Y. Aberrant DNA methylation results in altered gene expression in non-alcoholic steatohepatitis-related hepatocellular carcinomas. J Cancer Res Clin Oncol, 146:2461-2477, 2020

133. Tsutsui K, Takahashi A, Mori T, Namikawa K, Yamazaki N. Secretory carcinoma of the skin arising on the eyelid, distinguished by immunohistochemical markers and fluorescence in situ hybridization. J Dermatol, 47:e99-e100, 2020

134. Yamada S, Muto J, De Leon JCA, Kumai T, Ito K, Murayama K, Hama N, Nakano Y, Satomi K, Arai Y, Shibata T, Inoue T, Nobusawa S, Ichimura K, Hirose Y, Abe M. Primary spinal intramedullary Ewing-like sarcoma harboring CIC-DUX4 translocation: a similar cytological appearance as its soft tissue counterpart but no lobulation in association with desmoplastic stroma. Brain Tumor Pathol, 37:111-117, 2020

135. Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H. Multiplex gene-panel testing for lung cancer patients. Pathol Int, 70:921-931, 2020

136. Yatabe Y. Reassessing the SCLC Subtypes. J Thorac Oncol, 15:1819-1822, 2020

137. Yokota T, Saito Y, Takamaru H, Sekine S, Nakajima T, Yamada M, Sakamoto T, Taniguchi H, Kushima R, Tsukamoto S, Shida D, Kanemitsu Y, Matsuda T. Spontaneous Regression of Mismatch Repair-Deficient Colon Cancer: A Case Series. Clin Gastroenterol Hepatol, 2020

138. Yoshida KI, Machado I, Motoi T, Parafioriti A, Lacambra M, Ichikawa H, Kawai A, Antonescu CR, Yoshida A. NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma. Am J Surg Pathol, 44:719-728, 2020

139. Yoshiyama T, Munakata W, Maeshima A, Umesaki A, Yamaga H, Nishiyama A, Nakajo T, Tanaka Y, Matsumoto H, Terada T. [A Case of Erdheim-Chester Disease that was Difficult to Differentiate from Meningioma]. No Shinkei Geka, 48:809-818, 2020

Book

1. Yatabe Y, Borczuk AC, Cooper WA, Dacic S, Kerr KM, Moreira AL, Tsao MS (ed), The IASLC Atlas of Diagnostic Immunohistochemistry, Denver, IASLC press, 2020